XLO Stock Overview
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Xilio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.62 |
| 52 Week High | US$14.86 |
| 52 Week Low | US$1.95 |
| Beta | 0 |
| 1 Month Change | 33.21% |
| 3 Month Change | 56.49% |
| 1 Year Change | -65.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.38% |
Recent News & Updates
Shareholder Returns
| XLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | -0.8% | 1.7% |
| 1Y | -65.3% | 4.3% | -9.6% |
Return vs Industry: XLO underperformed the US Biotechs industry which returned 4.3% over the past year.
Return vs Market: XLO underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| XLO volatility | |
|---|---|
| XLO Average Weekly Movement | 14.9% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: XLO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: XLO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 78 | Rene Russo | https://www.xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases.
Xilio Therapeutics, Inc. Fundamentals Summary
| XLO fundamental statistics | |
|---|---|
| Market Cap | US$99.21m |
| Earnings (TTM) | -US$85.46m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs XLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$85.46m |
| Earnings | -US$85.46m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 7.7% |
How did XLO perform over the long term?
See historical performance and comparison